Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock-Based Compensation

The Stock-Based Compensation (SBC) of Recursion Pharmaceuticals (RXRX) as of Oct 15, 2026 is 111.22 M USD. In the previous year, Stock-Based Compensation (SBC) was 81.69 M USD — a change of 36.16% (higher).

Stock-Based Compensation

111.22 MUSD

YoY

36.16%

Last updated:

Stock-Based Compensation (SBC) of Recursion Pharmaceuticals is 2025 111.22 M USD. Stock-Based Compensation (SBC) of Recursion Pharmaceuticals was 2024 81.69 M USD. It decreases by 36.16% higher compared to the previous year.

The Recursion Pharmaceuticals Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
1.39 M USD
Jan 1, 2020
4.29 M USD
Jan 1, 2021
14.84 M USD
Jan 1, 2022
27.91 M USD
Jan 1, 2023
53.50 M USD
Jan 1, 2024
81.69 M USD
Jan 1, 2025
111.22 M USD
The Recursion Pharmaceuticals Stock-Based Compensation history
YEARStock-Based CompensationYoY
111.22 MUSD+36.16%
81.69 MUSD+52.68%
53.50 MUSD+91.71%
27.91 MUSD+88.04%
14.84 MUSD+245.81%
4.29 MUSD+209.89%
1.39 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals Inc is a biotechnology company based in Salt Lake City, Utah, operating in the Health Care sector. The company went public via an IPO on April 16, 2021. It employs approximately 600 people. Recursion Pharmaceuticals utilizes automation, artificial intelligence, and machine learning technologies to discover novel medicines. The company's platform, referred to as the Recursion Operating System (OS), integrates physical and digital components to map and navigate biological and chemical relationships. The company's approach involves iterative loops between wet lab biology and chemistry data, organized into cycles with computational tools to translate digital hypotheses into validated insights. Recursion Pharmaceuticals has clinical programs including REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is described as an orally bioavailable, superoxide scavenger small molecule being developed for the treatment of cerebral cavernous malformations. The company's website is www.recursion.com. It is listed under the ticker symbol RXRX with ISIN US75629V1044. The company's headquarters are located in Salt Lake City, Utah. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Stock-Based Compensation (SBC) of Recursion Pharmaceuticals is 111.22 M USD in 2025.

Stock-Based Compensation (SBC) of Recursion Pharmaceuticals changed from 81.69 M USD to 111.22 M USD, representing a 36.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Recursion Pharmaceuticals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Recursion Pharmaceuticals